Your browser doesn't support javascript.
loading
Fatty acid synthase as a potential new therapeutic target for cervical cancer.
Nascimento, Jéssica; Mariot, Camila; Vianna, Débora R B; Kliemann, Lúcia M; Chaves, Paula S; Loda, Massimo; Buffon, Andréia; Beck, Ruy C R; Pilger, Diogo A.
Afiliação
  • Nascimento J; Universidade Federal do Rio Grande do Sul, Faculdade de Farmácia, Av. Ipiranga, 2752, 90610-000 Porto Alegre, RS, Brazil.
  • Mariot C; Universidade Federal do Rio Grande do Sul, Faculdade de Farmácia, Av. Ipiranga, 2752, 90610-000 Porto Alegre, RS, Brazil.
  • Vianna DRB; Universidade Federal do Rio Grande do Sul, Faculdade de Farmácia, Av. Ipiranga, 2752, 90610-000 Porto Alegre, RS, Brazil.
  • Kliemann LM; Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre e Faculdade de Medicina, Departamento de Patologia, Rua Ramiro Barcelos, 2400, 90035-002 Porto Alegre, RS, Brazil.
  • Chaves PS; Universidade Federal do Rio Grande do Sul, Faculdade de Farmácia, Av. Ipiranga, 2752, 90610-000 Porto Alegre, RS, Brazil.
  • Loda M; Weil Cornell Medicine, Department of Pathology and Laboratory Medicine, 1300 York Avenue, New York Presbyterian-Weill Cornell Campus, New York, NY, 10065, USA.
  • Buffon A; New York Genome Center Affiliate Member, 101 Avenue of the Americas, New York, NY, 10013, USA.
  • Beck RCR; Broad Institute of MIT and Harvard University, 415 Main Street, Cambridge, MA, 2142, USA.
  • Pilger DA; Universidade Federal do Rio Grande do Sul, Faculdade de Farmácia, Av. Ipiranga, 2752, 90610-000 Porto Alegre, RS, Brazil.
An Acad Bras Cienc ; 94(2): e20210670, 2022.
Article em En | MEDLINE | ID: mdl-35507982
Fatty acid synthase (FASN) is the rate-limiting enzyme for the de novo synthesis of fatty acids in the cytoplasm of tumour cells. Many tumour cells express high levels of FASN, and its expression is associated with a poorer prognosis. Cervical cancer is a major public health problem, representing the fourth most common cancer affecting women worldwide. To date, only a few in silico studies have correlated FASN expression with cervical cancer. This study aimed to investigate in vitro FASN expression in premalignant lesions and cervical cancer samples and the effects of a FASN inhibitor on cervical cancer cells. FASN expression was observed in all cervical cancer samples with increased expression at more advanced cervical cancer stages. The FASN inhibitor (orlistat) reduced the in vitro cell viability of cervical cancer cells (C-33A, ME-180, HeLa and SiHa) in a time-dependent manner and triggered apoptosis. FASN inhibitor also led to cell cycle arrest and autophagy. FASN may be a potential therapeutic target for cervical cancer, and medicinal chemists, pharmaceutical researchers and formulators should consider this finding in the development of new treatment approaches for this cancer type.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: An Acad Bras Cienc Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: An Acad Bras Cienc Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil